Literature DB >> 19326192

Informative study designs to identify true parameter-covariate relationships.

Phey Yen Han1, Carl M J Kirkpatrick, Bruce Green.   

Abstract

This study explored how study design influences the probability of selecting a 'true' covariate from two competing covariate models. The probability of selecting the 'True Model' (lean body weight on clearance) over the 'False Model' (total body weight (WT) on clearance) was compared for designs where WT was either lognormally distributed (i.e. non-stratified), or stratified into 3 equal strata. The probability of selecting the 'True Model' increased as the WT inclusion criterion widened, and was always greater under the stratified design. Incorporating stratification into study designs, in combination with a wide covariate range, can aid identification of true parameter-covariate relationships. This has particular importance if the model is to be extrapolated beyond the studied population (e.g. dosing in obesity).

Entities:  

Mesh:

Year:  2009        PMID: 19326192     DOI: 10.1007/s10928-009-9115-y

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  23 in total

1.  Assessment of actual significance levels for covariate effects in NONMEM.

Authors:  U Wählby; E N Jonsson; M O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-06       Impact factor: 2.745

Review 2.  Population pharmacokinetics I: background, concepts, and models.

Authors:  Ene I Ette; Paul J Williams
Journal:  Ann Pharmacother       Date:  2004-08-24       Impact factor: 3.154

Review 3.  Pharmacokinetics/Pharmacodynamics and the stages of drug development: role of modeling and simulation.

Authors:  Jenny Y Chien; Stuart Friedrich; Michael A Heathman; Dinesh P de Alwis; Vikram Sinha
Journal:  AAPS J       Date:  2005-10-07       Impact factor: 4.009

4.  Non-Bayesian knowledge propagation using model-based analysis of data from multiple clinical studies.

Authors:  Jakob Ribbing; Andrew C Hooker; E Niclas Jonsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-11-08       Impact factor: 2.745

5.  Compartmental pharmacokinetics of dantrolene in adults: do malignant hyperthermia association dosing guidelines work?

Authors:  Tobias Podranski; Thomas Bouillon; Peter M Schumacher; Akikio Taguchi; Daniel I Sessler; Andrea Kurz
Journal:  Anesth Analg       Date:  2005-12       Impact factor: 5.108

Review 6.  Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.

Authors:  F E Harrell; K L Lee; D B Mark
Journal:  Stat Med       Date:  1996-02-28       Impact factor: 2.373

7.  Quantification of lean bodyweight.

Authors:  Sarayut Janmahasatian; Stephen B Duffull; Susan Ash; Leigh C Ward; Nuala M Byrne; Bruce Green
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

8.  Some considerations on the design of population pharmacokinetic studies.

Authors:  Stephen Duffull; Tim Waterhouse; John Eccleston
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

9.  A standard weight descriptor for dose adjustment in the obese patient.

Authors:  Stephen B Duffull; Michael J Dooley; Bruce Green; Susan G Poole; Carl M J Kirkpatrick
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

10.  Development of a dosing strategy for enoxaparin in obese patients.

Authors:  Bruce Green; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

View more
  8 in total

1.  Design of pharmacokinetic studies for latent covariates.

Authors:  Chakradhar V Lagishetty; Carolyn V Coulter; Stephen B Duffull
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-12-10       Impact factor: 2.745

Review 2.  The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007.

Authors:  Sarah C McLeay; Glynn A Morrish; Carl M J Kirkpatrick; Bruce Green
Journal:  Clin Pharmacokinet       Date:  2012-05-01       Impact factor: 6.447

Review 3.  Covariate pharmacokinetic model building in oncology and its potential clinical relevance.

Authors:  Markus Joerger
Journal:  AAPS J       Date:  2012-01-25       Impact factor: 4.009

4.  Pharmacokinetics of Telavancin at Fixed Doses in Normal-Body-Weight and Obese (Classes I, II, and III) Adult Subjects.

Authors:  Kristen L Bunnell; Manjunath P Pai; Monica Sikka; Susan C Bleasdale; Eric Wenzler; Larry H Danziger; Keith A Rodvold
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

5.  Population pharmacokinetics of bedaquiline (TMC207), a novel antituberculosis drug.

Authors:  Sarah C McLeay; Peter Vis; Rolf P G van Heeswijk; Bruce Green
Journal:  Antimicrob Agents Chemother       Date:  2014-06-23       Impact factor: 5.191

6.  The Impact of Model-Misspecification on Model Based Personalised Dosing.

Authors:  David A J McDougall; Jennifer Martin; E Geoffrey Playford; Bruce Green
Journal:  AAPS J       Date:  2016-06-15       Impact factor: 4.009

7.  Pharmacokinetics of ceftaroline in normal body weight and obese (classes I, II, and III) healthy adult subjects.

Authors:  Julie Ann Justo; Stockton M Mayer; Manjunath P Pai; Melinda M Soriano; Larry H Danziger; Richard M Novak; Keith A Rodvold
Journal:  Antimicrob Agents Chemother       Date:  2015-04-20       Impact factor: 5.191

8.  Evaluation of Concomitant Antiretrovirals and CYP2C9/CYP2C19 Polymorphisms on the Pharmacokinetics of Etravirine.

Authors:  Bruce Green; Herta Crauwels; Thomas N Kakuda; Simon Vanveggel; Anne Brochot
Journal:  Clin Pharmacokinet       Date:  2017-05       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.